Semax

Semax – Educational Overview

For Informational & Research Purposes Only.

What Is Semax?

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). It was originally developed in Russia and has been studied for its potential effects on cognitive function, neuroprotection, and neurotrophic activity.

In certain countries, Semax has been used clinically under medical supervision. However, it is not approved by the U.S. Food and Drug Administration (FDA).

Development Background

Semax was developed by researchers at the Institute of Molecular Genetics and has been studied in Russia for several decades. It has been investigated in the context of stroke recovery, cognitive disorders, and stress-related conditions.

Outside of specific national approvals, it remains an investigational compound.

Proposed Mechanisms of Action (Research Context)

Research suggests that Semax may:

• Influence brain-derived neurotrophic factor (BDNF) expression

• Modulate neurotransmitter systems, including dopamine and serotonin pathways

• Exhibit neuroprotective and antioxidant effects

• Affect inflammatory signaling in neural tissue

These findings are based on experimental and regional clinical studies; broader international validation is limited.

Important Note

This page is provided for research & educational purposes only.
Semax is not an FDA‑approved medication and should not be used without appropriate medical oversight in jurisdictions where it may be regulated.